Hyundai Bioscience Co. Ltd (048410) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hyundai Bioscience Co. Ltd (048410) has a cash flow conversion efficiency ratio of -0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.51 Billion ≈ $-2.38 Million USD) by net assets (₩110.28 Billion ≈ $74.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hyundai Bioscience Co. Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Hyundai Bioscience Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 048410 total debt and obligations for a breakdown of total debt and financial obligations.
Hyundai Bioscience Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hyundai Bioscience Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tangrenshen Group Co Ltd
SHE:002567
|
0.028x |
|
Beijing Hualu Baina Film TV
SHE:300291
|
0.001x |
|
Molinos Agro SA
BA:MOLA
|
-1.906x |
|
Tianma Bearing Group Co Ltd
SHE:002122
|
0.003x |
|
MannKind Corp
NASDAQ:MNKD
|
-0.527x |
|
Group Up Industrial Co Ltd
TWO:6664
|
0.027x |
|
Shandong Jincheng Pharmaceutical and Chemical Co Ltd
SHE:300233
|
0.021x |
|
Southside Bancshares, Inc.
NASDAQ:SBSI
|
0.048x |
Annual Cash Flow Conversion Efficiency for Hyundai Bioscience Co. Ltd (2008–2024)
The table below shows the annual cash flow conversion efficiency of Hyundai Bioscience Co. Ltd from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Hyundai Bioscience Co. Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩39.44 Billion ≈ $26.73 Million |
₩2.26 Billion ≈ $1.53 Million |
0.057x | +143.12% |
| 2023-12-31 | ₩45.27 Billion ≈ $30.68 Million |
₩-6.01 Billion ≈ $-4.07 Million |
-0.133x | +53.28% |
| 2022-12-31 | ₩58.24 Billion ≈ $39.47 Million |
₩-16.54 Billion ≈ $-11.21 Million |
-0.284x | -3148.24% |
| 2021-12-31 | ₩61.57 Billion ≈ $41.73 Million |
₩-538.48 Million ≈ $-364.92K |
-0.009x | -105.97% |
| 2020-12-31 | ₩51.22 Billion ≈ $34.71 Million |
₩7.50 Billion ≈ $5.08 Million |
0.146x | -25.02% |
| 2019-12-31 | ₩46.99 Billion ≈ $31.84 Million |
₩9.18 Billion ≈ $6.22 Million |
0.195x | +58.00% |
| 2018-12-31 | ₩40.48 Billion ≈ $27.44 Million |
₩5.01 Billion ≈ $3.39 Million |
0.124x | +203.33% |
| 2017-12-31 | ₩30.89 Billion ≈ $20.93 Million |
₩-3.70 Billion ≈ $-2.50 Million |
-0.120x | +49.76% |
| 2016-12-31 | ₩18.21 Billion ≈ $12.34 Million |
₩-4.34 Billion ≈ $-2.94 Million |
-0.238x | -6808.19% |
| 2015-12-31 | ₩24.60 Billion ≈ $16.67 Million |
₩87.36 Million ≈ $59.20K |
0.004x | -93.48% |
| 2014-12-31 | ₩22.49 Billion ≈ $15.24 Million |
₩1.22 Billion ≈ $829.60K |
0.054x | -80.56% |
| 2011-12-31 | ₩14.17 Billion ≈ $9.61 Million |
₩3.97 Billion ≈ $2.69 Million |
0.280x | +35.95% |
| 2008-12-31 | ₩50.36 Billion ≈ $34.13 Million |
₩10.37 Billion ≈ $7.03 Million |
0.206x | -- |
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.